Recent studies have shown that even low amounts of D9-tetrahydrocannbinol (THC) within a cannabidiol (CBD) product can result in positive 11-nor-9-carboxy-D9- tetrahydrocannabinol (THC-COOH; a metabolite of THC) urine drug screens.
Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users. Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations,
Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on
Abstract: Recent approval of Epidiolex (pharmaceutical cannabidiol/CBD) for the treatment of Lennox Gastaut syndrome (LGS) and Dravet syndrome highlights a therapeutic efficacy of CBD in the treatment of epilepsy.
Introduction. Despite widespread legalization, the impact of medicinal cannabis use on patient level health and quality of life has not been carefully evaluated. The objective of this study was to
All too often neglected, maximal quality improvement in the setting of life-limiting illness and noxious symptomatology is a worthy medical, public health, and humanitarian goal. The World Health Organization estimates […]
August 16, 2022
Abstract Objectives: Post-traumatic Stress Disorder (PTSD) is a diagnosis of extreme anxiety caused by a traumatic event. Less than 10% of individuals who have experienced severe trauma will develop this […]
August 15, 2023
ABSTRACT Introduction. Cannabis sativa has been cultivated for human use for about 5,000 years, and has likewise been used in the treatment of epilepsy for thousands of years. State of […]
March 21, 2024
Please use this link to access this publication. Abstract Background: Cannabidiol (CBD), one of the major cannabinoids derived from the cannabis plant, is available over the counter. CBD is often used […]
December 17, 2024
Please use this link to access this publication. Abstract Objective Cannabidiol (CBD) has a proposed novel role in the management of anxiety owing to its actions on the endocannabinoid system. […]
July 2, 2024
Abstract Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse […]
November 10, 2021
Please use this link to access this publication. Abstract Background The burden of illness for PTSD is staggering and confers significant interference in work, social functioning, as well as increased risk for […]
January 15, 2024
Abstract Introduction: Sleeplessness, i.e., getting <7hours sleep/night (L7H), causes significant health and financial problems for individuals and industry. Sleeplessness is classified into 4 categories: difficulty initiating sleep (DIS), difficulty […]
August 26, 2021
Abstract: Nabilone is a synthetic cannabinoid that has shown promise for the treatment of posttraumatic stress disorder (PTSD)Yrelated insomnia and nightmares as well as efficacy in the management of chronic […]
June 14, 2021
Abstract Objectives: This study aimed to characterize use and perceptions of cannabidiol (CBD) products. Materials and Methods: Participants aged 16–65 years in Canada (n=15,042) and the United States (n=30,288) completed measures on […]
January 15, 2024
